Cilo Cybin progressing with JSE listing, expansion plans
Midrand-based cannabis pharmaceuticals and health device manufacturer Cilo Cybin intends to use capital raised during its planned JSE listing to ramp up cannabis product production, as well as enter and grow its health device and analysis business.
Cilo Cybin CEO and president Gabriel Theron tells Engineering News that, since the opening of the company's initial public offering (IPO) on September 9, that is has received significant interest in investment opportunities.
“It has been an interesting journey so far. We have been contacted by a lot of the banks and retail investors. We are [also] getting quite a bit of interest from the public [about how they can] participate.”
The IPO will close on November 4, after which Cilo Cybin will be added the the JSE board on November 14.
Normally, he says, IPO shares start at about R1-million as a minimum investment. “We have done it [at] R1 000 [to make it] inclusive. We want to let everybody to be able to get in.”
After the closing of the IPO, Theron says the company will approach some high-net-worth individuals with an investment proposal.
In terms of production, Cilo Cybin has recently produced “quite a bit of volume” in an effort to bolster its stock holding, thereby enabling the company to focus on converting the semi-finished product into oils and other final products, he says.
Cilo Cybin currently holds three cannabis production licenses, including one of 80 issued nationally for cannabis cultivation; one of three issued nationally for good manufacturing processes of cannabis to be used an active pharmaceutical ingredient (API); and the only good manufacturing process license nationally for converting cannabis products into their final form.
Therefore, Cilo Cybin is permitted to undertake the entire value chain of cannabis product production, from cultivation, API to a final product.
However, a challenge posed to the cannabis market is harm that has been done by certain cannabidiol (CBD) manufactures who have released products into the market with a CBD formulation that is too high. This has resulted in the medication not having the desired effect and consumers developing a reluctance to buy other CBD products.
This means Cilo Cybin has to re-educate the market, a move it chose to undertake by keeping its products away from mainstream distributors. As such, the company’s products are instead marketed as practitioner brans, available through doctors and recommended by word of mouth. “It is a slower growth, but we believe it is more sustainable,” says Theron.
In this regard, he says Cilo Cybin has also experienced a good degree of repetitive buying.
Part of the JSE listing endeavour is to upscale the company’s manufacturing side of the business, as well as to get European Union (EU) accreditation – an EU Good Manufacturing Process accreditation.
Getting entry into the EU market bloc will result of significant interest in Cilo Cybin’s products and enable the company to focus more on increasing production to meet new demand, says Theron.
Scaling up production is dependent on offtake of products, and in this regard, he says the company has modestly forecasted increasing production to 150 kg of oil a month, which requires about 2 t of cannabis flower.
Based on increased offtake, Cilo Cybin intends to phase most of its sales from bulk orders over to finished products. Changing from bulk to instead selling finished products will result in profits increasing about three-fold, says Theron.
Further, transitioning from bulk to final product sales will translate into about 150 000 units of 30 ml bottles a month. Currently, Cilo Cybin is able to produce 100 000 such bottles a month.
In terms of exports, the company is currently doing shipments to Australia, while a shipment to South America was also recently done.
“We are speaking to [offtakers] in India. That will be quite a significant [volume],” he says. For India, Cilo is targeting 50 000 units a month, scaling to 200 000 as soon as demand arises.
However, Europe remains Cilo Cybin’s first export prize, driven by plans to open the bloc’s recreational use of cannabis in 2025/26, says Theron.
Besides the cannabis product side of business, Cilo Cybin also wants to increasingly shift focus into a US-based human genetics analysis company, as well as into its health device company.
In terms of health devices and products, Cilo Cybin has a keen eye on devices that can analyse human brains on both an emotional and physical level, the latter to determine severity of physical impacts, such as a concussion. This device would also be able to determine whether medication is working as intended and any consequences of medication on the brain.
Another item of technology of interest to the company is one to test human’s nervous system, such as factors of inflammation, stress, hormonal levels, mineral levels and brain receptor levels.
Comments
Press Office
Announcements
What's On
Subscribe to improve your user experience...
Option 1 (equivalent of R125 a month):
Receive a weekly copy of Creamer Media's Engineering News & Mining Weekly magazine
(print copy for those in South Africa and e-magazine for those outside of South Africa)
Receive daily email newsletters
Access to full search results
Access archive of magazine back copies
Access to Projects in Progress
Access to ONE Research Report of your choice in PDF format
Option 2 (equivalent of R375 a month):
All benefits from Option 1
PLUS
Access to Creamer Media's Research Channel Africa for ALL Research Reports, in PDF format, on various industrial and mining sectors
including Electricity; Water; Energy Transition; Hydrogen; Roads, Rail and Ports; Coal; Gold; Platinum; Battery Metals; etc.
Already a subscriber?
Forgotten your password?
Receive weekly copy of Creamer Media's Engineering News & Mining Weekly magazine (print copy for those in South Africa and e-magazine for those outside of South Africa)
➕
Recieve daily email newsletters
➕
Access to full search results
➕
Access archive of magazine back copies
➕
Access to Projects in Progress
➕
Access to ONE Research Report of your choice in PDF format
RESEARCH CHANNEL AFRICA
R4500 (equivalent of R375 a month)
SUBSCRIBEAll benefits from Option 1
➕
Access to Creamer Media's Research Channel Africa for ALL Research Reports on various industrial and mining sectors, in PDF format, including on:
Electricity
➕
Water
➕
Energy Transition
➕
Hydrogen
➕
Roads, Rail and Ports
➕
Coal
➕
Gold
➕
Platinum
➕
Battery Metals
➕
etc.
Receive all benefits from Option 1 or Option 2 delivered to numerous people at your company
➕
Multiple User names and Passwords for simultaneous log-ins
➕
Intranet integration access to all in your organisation